Informative gene network for chemotherapy-induced peripheral neuropathy
暂无分享,去创建一个
Jian Wang | Cielito Reyes-Gibby | Sai-Ching Yeung | Sanjay Shete | Jian Wang | S. Shete | S. Yeung | C. Reyes-Gibby
[1] M. Spitz,et al. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. , 2013, Journal of pain and symptom management.
[2] Jun Liang,et al. Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer , 2010, Journal of Korean medical science.
[3] G. Bennett,et al. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy , 2004, Pain.
[4] G. Abrams,et al. Associations Between Cytokine Genes and a Symptom Cluster of Pain, Fatigue, Sleep Disturbance, and Depression in Patients Prior to Breast Cancer Surgery , 2015, Biological research for nursing.
[5] G. Bennett,et al. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. , 2008, Pain medicine.
[6] W. Vach,et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients , 2013, Acta oncologica.
[7] Seung-Yong Jeong,et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer , 2013, Cancer Chemotherapy and Pharmacology.
[8] K. Stankovic,et al. Metabolomic and Network Analysis of Pharmacotherapies for Sensorineural Hearing Loss , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[9] L. Radbruch,et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines , 1999, Pain.
[10] P. Albertsson,et al. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. , 2010, Oncology letters.
[11] A. Argyriou,et al. Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? , 2010, European journal of neurology.
[12] Yen-Chung Chen,et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX‐4 treatment in Asian patients with colorectal carcinoma , 2010, Cancer science.
[13] R. Lothe,et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study , 2007, Journal of Translational Medicine.
[14] E. Ong. Controlled-Release Oxycodone in the Treatment of Neuropathic Pain of Nonmalignant and Malignant Causes , 2008, Oncology.
[15] A. Khrunin,et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients , 2010, The Pharmacogenomics Journal.
[16] M. Baiget,et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy , 2009, British Journal of Cancer.
[17] G. Ehninger,et al. The T_T genotype within the NME1 promoter single nucleotide polymorphism −835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia , 2012, Leukemia & lymphoma.
[18] R. Milne,et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.
[19] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[20] F. Carvalho,et al. Interleukin-1β genotype and circulating levels in cancer patients: metastatic status and pain perception. , 2014, Clinical biochemistry.
[21] P. Novotny,et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. , 2003, The journal of supportive oncology.
[22] E. Gamelin,et al. Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway , 2007, Clinical Cancer Research.
[23] H. Thaler,et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms , 1994, Neurology.
[24] C. Reyes-Gibby,et al. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Caldas,et al. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.
[26] M. Stillman,et al. Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.
[27] L. Carey,et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] E. Bruera,et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. , 2008, The Lancet. Oncology.
[29] K. Kumamoto,et al. Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients , 2013, Oncology letters.
[30] K. Kitagawa,et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. , 2010, International journal of clinical pharmacology and therapeutics.
[31] K. Stankovic,et al. A Comprehensive Network and Pathway Analysis of Human Deafness Genes , 2013, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[32] W. Vach,et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.
[33] Yusuke Nakamura,et al. A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 , 2012, Clinical Cancer Research.
[34] Y. Ling,et al. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy. , 2013, Molecular medicine reports.
[35] F. Matsuda,et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. , 2010, Cancer epidemiology.
[36] A. Caraceni,et al. An international survey of cancer pain characteristics and syndromes , 1999, PAIN.
[37] A. González-Neira,et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy , 2013, Journal of Medical Genetics.
[38] J. Lundeberg,et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. , 2012, Gene.
[39] B. Schmidt,et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. , 2012, The journal of pain : official journal of the American Pain Society.
[40] R. Albert,et al. The large-scale organization of metabolic networks , 2000, Nature.
[41] H. Chung,et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. , 2009, Gynecologic oncology.
[42] Junshik Hong,et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis , 2011, Cancer Chemotherapy and Pharmacology.
[43] H. Eom,et al. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. , 2010, Cancer genetics and cytogenetics.
[44] G. Y. Wong,et al. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy , 2007, Cancer.
[45] S. Steinberg,et al. ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel , 2008, Clinical Cancer Research.
[46] A. Gibson. The European Society for Medical Oncology (ESMO) , 2019, Annals of Oncology.
[47] E. Bruera,et al. The Influence of Tumor Necrosis Factor-α −308 G/A and IL-6 −174 G/C on Pain and Analgesia Response in Lung Cancer Patients Receiving Supportive Care , 2008, Cancer Epidemiology Biomarkers & Prevention.
[48] H. Goldschmidt,et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] M. Spitz,et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes , 2013, Supportive Care in Cancer.
[50] W. Vach,et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. , 2012, Basic & clinical pharmacology & toxicology.
[51] H. Goldschmidt,et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. , 2010, The Lancet. Oncology.
[52] L. Carey,et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel , 2012, Breast Cancer Research and Treatment.
[53] Jennie Malboeuf. Algorithm , 1994, Neurology.
[54] A. Argyriou,et al. Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy , 2009, Oncology.
[55] T. Rebbeck,et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia , 2003, British journal of haematology.
[56] M. Indelli,et al. Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients , 2010, Breast Cancer Research and Treatment.
[57] N. Cherny. Opioid analgesics: comparative features and prescribing guidelines. , 1996, Drugs.
[58] C. Punt,et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. , 2009, European journal of cancer.
[59] P. Zis,et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. , 2008, Pain medicine.
[60] H. Goldschmidt,et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients , 2011, Haematologica.
[61] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] S. Maier,et al. Immune regulation of central nervous system functions: from sickness responses to pathological pain , 2005, Journal of internal medicine.
[63] M. Dolan,et al. Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy , 2012, Clinical Cancer Research.
[64] A. Dickenson,et al. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy , 2003, Brain Research.
[65] P. Tonali,et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity , 2011, Cancer Chemotherapy and Pharmacology.
[66] M. Loriot,et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] G. Mulligan,et al. Genetic variation associated with bortezomib-induced peripheral neuropathy , 2011, Pharmacogenetics and genomics.
[68] A. Khrunin,et al. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. , 2014, Pharmacogenomics.
[69] C. Bokemeyer,et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] G. Hortobagyi,et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221) , 2011, Breast Cancer Research and Treatment.
[71] M. Loriot,et al. Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy , 2006, Clinical Cancer Research.
[72] E. Bruera,et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. , 2009, Journal of pain and symptom management.
[73] O. Mir,et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[74] Robert Brown,et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] J. Stinson,et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. , 2007, Pain research & management.
[76] C. Loprinzi,et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. , 2008, European journal of cancer.
[77] Hyo-jin Kim,et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. , 2009, Oncology reports.
[78] T. Nurmikko,et al. EFNS guidelines on pharmacological treatment of neuropathic pain , 2006, European journal of neurology.
[79] D. Sargent,et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.
[80] S. Steinberg,et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. , 2006, European journal of cancer.
[81] Raya Khanin,et al. How Scale-Free Are Biological Networks , 2006, J. Comput. Biol..
[82] A. Navarro,et al. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. , 2011, Leukemia research.
[83] E. Wiemer,et al. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity , 2013, Clinical Cancer Research.
[84] David Schiff,et al. Neurologic complications of chemotherapy agents , 2007, Current opinion in neurology.
[85] L. Carey,et al. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy , 2014, Breast Cancer Research and Treatment.
[86] M. Taron,et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] M. Clark,et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. , 2012, Lung cancer.
[88] G. Bennett,et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells , 2008, Experimental Neurology.
[89] P. Vivas-Mejia,et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models , 2008, British journal of pharmacology.
[90] K. Nathanson,et al. Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF) , 2012, Front. Endocrin..
[91] J. Aparicio,et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[92] Harald Breivik,et al. International Association for the Study of Pain: update on WHO-IASP activities. , 2002, Journal of pain and symptom management.
[93] P. Söderkvist,et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. , 2009, Basic & clinical pharmacology & toxicology.
[94] Robert Brown,et al. Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity , 2013, Clinical Cancer Research.
[95] F. Innocenti,et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen , 2012, The Pharmacogenomics Journal.
[96] M. Friedlander,et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. , 2008, Current medicinal chemistry.
[97] S. Maier,et al. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.
[98] M. Relling,et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] B. Schmidt,et al. Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. , 2014, The journal of pain : official journal of the American Pain Society.
[100] Joon-Oh Park,et al. Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients , 2012, Cancer.
[101] J. Ahn,et al. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. , 2014, European journal of cancer.
[102] Y. Bang,et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker , 2008, BMC Cancer.
[103] Cristina Santos,et al. Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study , 2013, Cancer.